the outcome measure and 11 randomized, controlled trials as the data source. They conclude that both DES and DEB reduce TLR by w75% to 80% compared with POBA. This is supported by data from angiographic follow-up. Safety issues (death and myocardial infarction) were also considered. They go on to assess the probability of the best treatment and conclude that it is most likely to be treatment with DEB (60% likelihood).
I suspect most cardiologists experience some form of "brain freeze" when confronted with the results of an NMA, and I suspect most of us simply jump to the conclusions and hope the paper was well enough refereed so they are valid. Sadly, that may not always be true (2) .
Fortunately, there are several excellent and readable reviews on the topic, not only in statistical journals (3) (4) (5) (6) , but also mainstream journals such as the British Medical Journal (7) and Annals of Internal Medicine (8,9) that demystify the topic.
In short, NMAs are used to draw comparisons between outcomes of treatments that have been either directly or indirectly compared by making use of comparison treatments they share in common.
Here is a simple step-by-step way to begin to judge the strength of evidence and some suggestions about how to present NMAs to make it even easier to make that assessment (skip to the last paragraph if you have no interest in NMAs). From the Cleveland Clinic, Cleveland, Ohio. Dr. Ellis has reported that he has no relationships relevant to the contents of this paper to disclose. 4. Make sure random-effects modeling, rather than fixed-effects modeling was used (the latter assumes that there is a negligible amount of heterogeneity, which is usually incorrect).
5. Be skeptical about claims for ranking treatments in order of effect because as they are particularly prone to error (7).
Suggestions for better "network geometry" graphic depiction ( Figure 1 ) are the following: Second, reviewing their Figure 1B , one sees at least 3 trials bridging each treatment, which is strength.
Conversely, there are some issues of concern. First, including underpowered trials undercuts the reliability of the results. Because of the large expected difference in TLR between POBA and the other treatments, trials comparing these treatments can be small (e.g., 43 patients per group, assuming 40% vs.
10% TLR with 85% power). However, DEB versus DES trials, attempting to see differences on the order of 15% versus 10% with the same power, need to include w820 patients in each group, more patients per group than are available in aggregate in the NMA that we are When Is a Meta-Analysis Good Enough?
M A R C H 2 0 1 5 : 3 9 5 -7 for many comparisons, I 2 values exceed the 50% threshold.
To summarize, the magnitude of DEB and DES benefit for TLR compared with POBA is such that, despite the concerns raised, it is most certainly correct in order and general magnitude. Conclusions regarding the relative efficacy and safety of DEB and DES in this circumstance, particularly generalizing to current devices, are premature.
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